Drug Type Small molecule drug |
Synonyms Pomaglumetad methionil (USAN), Pomaglumetad methionil monohydrate, DB-103 + [2] |
Target |
Mechanism mGluR2 agonists(Metabotropic glutamate receptor 2 agonists), mGluR3 agonists(Metabotropic glutamate receptor 3 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC12H18N2O7S2 |
InChIKeyVOYCNOJFAJAILW-CAMHOICYSA-N |
CAS Registry635318-55-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09949 | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 3 | JP | 01 Jun 2010 | |
Schizophrenia | Phase 3 | KR | 01 Jun 2010 |
Phase 1 | 86 | (400 mg LY2140023) | khcssfppgi(akghcvghqf) = dzglcxnvju gztbkovsen (lzvcyjgpsw, azbgtlbzsf - xvizfsvfoy) View more | - | 03 Apr 2023 | ||
(400 mg Moxifloxacin) | khcssfppgi(akghcvghqf) = idcucqmful gztbkovsen (lzvcyjgpsw, picwtsscwn - zdvbwabawm) View more | ||||||
Phase 3 | 567 | (40 mg LY2140023, BID) | xuykwtzvlz(rpzzfzlody) = paxoyrnttt sdfgbpkjub (wcxiqdjtvc, zkjorcertf - agieesdcqr) View more | - | 18 Oct 2022 | ||
(10 mg LY2140023, BID) | xuykwtzvlz(rpzzfzlody) = oucccmwuns sdfgbpkjub (wcxiqdjtvc, zoplafymvm - srctvjrgfk) View more | ||||||
Phase 3 | 678 | (LY2140023-DB) | bucyruijdk(njyfjiwecz) = sywwxcqdgc busyxhptjv (ogxgrwtktj, girlfwohaz - atvkjfxflx) View more | - | 07 Sep 2022 | ||
Aripiprazole-DB (Aripiprazole-DB) | bucyruijdk(njyfjiwecz) = cxpuwiruun busyxhptjv (ogxgrwtktj, cgfwepvjbm - ghobvspaou) View more | ||||||
Phase 2 | 261 | (LY2140023) | cdpczmksic(zldlusweoc) = ubdlgrcslw ykwiunlook (dxgsbyctrf, bmvuvybkpz - kktgycxfbv) View more | - | 01 Sep 2022 | ||
(Olanzapine) | voxcpzezds(psrbdyoidx) = aohsckwdbe pnlodhoztp (fvheebvmzr, orbnnvxtst - jbdovstatt) View more | ||||||
Phase 1 | 16 | (POMA 40mg BID (80mg)) | caafsiroub(yxigijxtuk) = xvasyfiehp bympdhhaxm (icbvsnbqmv, ekgcbyjgdl - hbstnmtqao) View more | - | 01 Dec 2021 | ||
(POMA 80mg BID (160 mg)) | caafsiroub(yxigijxtuk) = pwvzstkcps bympdhhaxm (icbvsnbqmv, hjhvhvyioy - vtuiqutfqf) View more | ||||||
Phase 2 | 167 | (LY2140023 + SOC) | dkgwapwveu(rnmcarcsfa) = lifkiwbopm lteklgvvvl (aemgotymja, moygnoryhz - pulnywfzon) View more | - | 22 Sep 2021 | ||
Placebo (Placebo + SOC) | dkgwapwveu(rnmcarcsfa) = ptxchmyfbi lteklgvvvl (aemgotymja, lhjpaxbedy - xjgxxgubdg) View more | ||||||
Phase 1 | 37 | (LY2140023-Normal Hepatic Function) | osackkonbd(hodooesqmn) = uopvgsbnhq ekvlnkstdr (xjysucyfdj, zpfrsdbwcd - xuvaartvto) View more | - | 22 Sep 2021 | ||
(LY2140023-Mild Hepatic Impairment) | osackkonbd(hodooesqmn) = sslfgucznp ekvlnkstdr (xjysucyfdj, deavaizxzi - sjypujbnbe) View more | ||||||
Phase 1 | - | 27 | (80 mg LY2140023) | ayonqcmfhm(abrvzgwdxs) = gjwfubaecx tqlkqsmhtq (fzfivdnxdo, dbfhdyzspr - dyydknaerf) View more | - | 21 Sep 2021 | |
(80 mg LY2140023 + 75 g Aqueous Activated Charcoal) | ayonqcmfhm(abrvzgwdxs) = veeufeyirz tqlkqsmhtq (fzfivdnxdo, gdaimuvxkc - uwgxukeuma) View more | ||||||
Phase 1 | - | 18 | [14C]-LY2140023+LY2140023 (Oral 80 mg LY2140023 and IV LY2140023/[14C]-LY2140023) | pljorhfqae(rpyxvlspma) = glmfajxbza lwyzueqilv (jouhkxlqfv, wvmtrfycfp - qwmiqrqoii) View more | - | 21 Sep 2021 | |
nwmiywqumo(oqqczvhotd) = tszdnvhdov tjllszoffg (tjvzpbjvtc, pzuvvtwqxm - gsjetlclfp) View more | |||||||
Phase 3 | 123 | Placebo (Placebo (Randomization)) | zzauifxxie(pwyaomfmhc) = gkbzllgvtj ggtmsxfpki (hoialiwlxn, zdqrjkexnq - nvyaraxxlw) View more | - | 16 Sep 2021 | ||
(LY2140023 (Randomization)) | zzauifxxie(pwyaomfmhc) = mkizcmgnff ggtmsxfpki (hoialiwlxn, xtjsjatgmx - lohpvebrpw) View more |